Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives

Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives

Graves’ orbitopathy (GO) is a potentially sight-threatening and disfiguring, extrathyroidal manifestation of Graves’ disease. It often impairs patients’ qu ality of life, causing severe social and psychological sequelae. Intravenous glucocorticosteroids is currently the mainstay of therapy, but the...

Full description

Bibliographic Details
Main Authors:	Jakub Supronik, Małgorzata Szelachowska, Adam Kretowski, Katarzyna Siewko
Format:	Article
Language:	English
Published:	Bioscientifica 2022-11-01
Series:	Endocrine Connections
Subjects:	graves’ orbitopathy rituximab thyroid eye disease graves’ disease
Online Access:	https://ec.bioscientifica.com/view/journals/ec/11/12/EC-22-0303.xml

Similar Items

Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis
by: Tülay Şimşek, et al.
Published: (2017-01-01)

Thyroid eye disease or Graves’ orbitopathy: What name to use, and why it matters
by: Lilly H. Wagner, et al.
Published: (2022-11-01)

Tears as a Source of Biomarkers in the Diagnosis of Graves’ Orbitopathy
by: Diana Bajkowska, et al.
Published: (2022-11-01)

Role of genetics and epigenetics in Graves’ orbitopathy
by: Michele Marinò, et al.
Published: (2024-11-01)

Dermopathy, Acropachy and Orbitopathy in Graves’ Disease
by: James Young, et al.
Published: (2024-08-01)

Effectiveness of educational materials on levels of knowledge of thyroid associated orbitopathy in an endocrinology clinic
by: Wajiha J. Kheir, et al.
Published: (2023-12-01)

Steroid-resistant Graves' orbitopathy: Therapeutic options
by: Klet Sanja, et al.
Published: (2023-01-01)

Influence of biological sex, age and smoking on Graves’ orbitopathy – a ten-year tertiary referral center analysis
by: Michael Oeverhaus, et al.
Published: (2023-04-01)

Thyroid Receptor Antibody and the Development of Graves’ Orbitopathy: Clinical Experience of using Radioiodine Ablation in the Management of Graves’ Orbitopathy in post-iodine ablation hypothyroid patient
by: Edelyn Christina, et al.
Published: (2023-06-01)

Ocular surface disease index in Graves’ orbitopathy: a cross-sectional study
by: Maria Novella Maglionico, et al.
Published: (2024-12-01)

Incidence and risk factors for Graves’ orbitopathy in patients who underwent anti-inflammatory and immunosuppressive treatment during medical treatment for Graves’ disease: investigation of 1,553 cases with newly diagnosed Graves’ disease and proposal of a predictive score
by: Natsuko Watanabe, et al.
Published: (2023-11-01)

Efficacy of rituximab in treating steroid-resistant Graves’ orbitopathy in active moderate-to-severe and sight-threatening forms: A retrospective observation from China
by: Ziyin Zhang, et al.
Published: (2024-06-01)

Incidence of the postpartum diagnosis of thyroid eye disease in relation to thyroid function in Graves’ disease
by: Nami Suzuki, et al.
Published: (2025-01-01)

High IgG4 serum concentration is associated with active Graves orbitopathy
by: Michał Olejarz, et al.
Published: (2023-03-01)

Update on the surgical management of Graves’ orbitopathy
by: Joonyoung Baeg, et al.
Published: (2023-02-01)

Targeted immunotherapies for Graves’ thyroidal & orbital diseases
by: Alan Chun Hong Lee, et al.
Published: (2025-03-01)

Steroid Treatment Focused Management of Graves’ Ophthalmopathy
by: Condeng Y. H., et al.
Published: (2024-09-01)

Orbital Radiotherapy for Graves’ Ophthalmopathy: Single Institutional Experience of Efficacy and Safety
by: Madalina La Rocca, et al.
Published: (2025-02-01)

Inactive Graves’ orbitopathy: to treat or not to treat?
by: O. G. Panteleeva, et al.
Published: (2023-03-01)

Psychiatric complications in Graves’ disease
by: Mats Holmberg, et al.
Published: (2024-02-01)

Significance of HLA in Graves’ disease and Graves’ orbitopathy in Asian and Caucasian populations – a systematic review
by: Magdalena Stasiak, et al.
Published: (2023-09-01)

Iodine contrast should be avoided in patients with thyroid eye disease
by: Jane Z. Spadaro, et al.
Published: (2024-09-01)

Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab
by: Ilaria Muller, et al.
Published: (2024-04-01)

An Appraisal of the Preventive Effect of Statins on the Development of Graves’ Ophthalmopathy: A Hospital-Based Cohort Study
by: Grace Chia-Yen Hsu, et al.
Published: (2024-04-01)

Orbital Inflammation in Thyroid Eye Disease: Stress Responses and Their Implications
by: Tracy Aoun, et al.
Published: (2024-01-01)

Therapeutic effect of selective interleukin-2-inducible tyrosine kinase inhibitor in orbital fibroblasts from patients with Graves’ orbitopathy
by: Yeonjung Yoon, et al.
Published: (2024-09-01)

Hypo vs. hyperthyroid eye disease: is there any difference?
by: Bahram Eshraghi, et al.
Published: (2023-02-01)

Clinical utility of TSH receptor antibody levels in Graves’ orbitopathy: a comparison of two TSH receptor antibody immunoassays
by: Gabriela A. Bluszcz, et al.
Published: (2018-12-01)

Graves'orbitopathy: current imaging procedures
by: E Kirsch, et al.
Published: (2009-10-01)

Current imaging methods for assessing Graves` orbitopathy activity with particular emphasis on FDG-PET
by: Anna Ochmann, et al.
Published: (2023-08-01)

Correlation between Structural and Functional Changes in Patients with Raised Intraocular Pressure Due to Graves’ Orbitopathy
by: Freja Bagatin, et al.
Published: (2024-03-01)

Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves’ Orbitopathy: A Pilot Study
by: Joanna Rymuza, et al.
Published: (2022-07-01)

Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves’ orbitopathy: an observational study
by: Georgios Boutzios, et al.
Published: (2023-06-01)

Success Treatment of Severe and Active Graves’ Orbitopathy with Tocilizumab After Thyroidectomy and Maximum Dose of Intravenous Methylprednisolone
by: Laurentius Aswin Pramono
Published: (2023-10-01)

A combined transcriptomics and proteomics approach reveals S100A4 as a potential biomarker for Graves’ orbitopathy
by: Chiaw-Ling Chng, et al.
Published: (2024-09-01)

Endoscopic and transcaruncular medial wall decompression in unilateral graves’ orbitopathy: a multicenter randomized study
by: Mahmoud A. El-Samkary, et al.
Published: (2017-07-01)

Application of artificial intelligence in the assessment of thyroid eye disease (TED) - a scoping review
by: Chiaw-Ling Chng, et al.
Published: (2023-12-01)

ELF3-induced miR-182 inhibits adipogenic differentiation in Graves’ orbitopathy by targeting thyrotropin receptor
by: Sha Wang, et al.
Published: (2023-01-01)

The role of hormonal imbalance in the development of autoimmune dacryoadenitis in endocrine orbitopathy
by: V. G. Likhvantseva, et al.
Published: (2014-07-01)

Glucocorticoids Directly Affect Hyaluronan Production of Orbital Fibroblasts; A Potential Pleiotropic Effect in Graves’ Orbitopathy
by: Erika Galgoczi, et al.
Published: (2022-12-01)